Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines

• Published in: Cancers Vol. 12; no. 7; p. 1811
• Main Authors: Kuroiwa, Yuka, Nakayama, Jun, Adachi, Chihiro, Inoue, Takafumi, Watanabe, Shinya, Semba, Kentaro
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 06.07.2020; MDPI
• Subjects: Brain cancer; Breast cancer; Cancer therapies; Colonization; DNA microarrays; ErbB-2 protein; Gene expression; Kinases; Medical prognosis; Metastases; Metastasis; Molecular modelling; Mutation; Parenchyma; Phosphorylation; Studies; Survival analysis; Tumor cell lines; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12071811

HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype, and the molecular mechanisms of brain metastasis in HER2-positive breast cancer are unclear. In the present study, we performed intracranial injection using nine HER2-positive breast cancer cell lines to evaluate their proliferative activity in brain tissue. Our results show that UACC-893 and MDA-MB-453 cells rapidly proliferated in the brain parenchyma, while the other seven cell lines moderately or slowly proliferated. Among these nine cell lines, the proliferative activity in brain tissue was not correlated with either the HER2 level or the HER2 phosphorylation status. To extract signature genes associated with brain colonization, we conducted microarray analysis and found that these two cell lines shared 138 gene expression patterns. Moreover, some of these genes were correlated with poor prognosis in HER2-positive breast cancer patients. Our findings might be helpful for further studying brain metastasis in HER2-positive breast cancer.